

## **Richard Whitley, MD**

*Scientific Advisory Board Member*



**Richard Whitley, MD** is a member of the Altesa Scientific Advisory Board and most recently served on the Board of Directors of Gilead Sciences, Inc as well as the twelve-member NIH/NIAID Data Safety and Monitoring Board (DSMB) responsible for the safety, integrity and scientific validity of all NIH-funded COVID-19 vaccine trials in the United States. Dr. Whitley is a Distinguished Professor of Pediatrics, Professor of Microbiology, Medicine and Neurosurgery; Loeb Eminent Scholar Chair in Pediatrics; Co-Director, Division of Pediatric Infectious Diseases; Vice-Chair, Department of Pediatrics; Senior Scientist, Department of Gene Therapy; Scientist, Cancer Research and Training Center; Faculty, Gene Therapy Center; Senior Advisor for Drug Discovery and Development and Senior Leader, Pediatric Oncology Program, O'Neal Comprehensive Cancer Center at the University of Alabama, Birmingham. Dr. Whitley is responsible for the National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group, whose role is to perform clinical trials of antiviral therapies directed against medically important viral diseases of children and adults including viruses considered as threats to human health. His other research interest is in the translation of molecular biology to clinical application, particularly in the development of human monoclonal antibodies for therapy of herpes virus infections and engineering of herpes simplex virus for gene therapy. In 2013, he was named as the inaugural recipient of the Distinguished Clinical Research Scholar and Educator in Residence at the NIH Clinical Center.